Kiora Pharmaceuticals Announces Management Team Changes
Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J. Daniels, M.D., MBA, will depart from his role as Chief Development Officer on April 17, 2026, to pursue other opportunities. The Company has initiated a search for his successor. "Eric has made many important contributions to Kiora during his time with the Company," said Brian M. Strem, Ph.D., President and Chief Executive Officer
Biotechnology, Pharmaceuticals
2026-04-02 4:30 PM EDT | Kiora Pharmaceuticals, Inc.
Resverlogix Corp. Announces Issuance of MCTO by ASC
Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following an application made by the Company, and first announced on March 17, 2026 (the "Original Announcement"). The MCTO relates to Resverlogix's default on the prescribed deadl
Technology, Biotechnology, Healthcare and Hospitals
2026-04-02 7:15 AM EDT | Resverlogix Corp.
PreveCeutical Adopts Semi-Annual Financial Reporting
Vancouver, British Columbia--(Newsfile Corp. - April 1, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCID: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") announces that it has elected to rely on Coordinated Blanket Order 51-933 and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-93 allows eligible venture issuers listed on the Canadian Securities Exchange (the "CSE") to voluntarily move from a quarterly to a semi
Biotechnology, Pharmaceuticals, Health
2026-04-01 4:00 PM EDT | PreveCeutical Medical Inc.
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's pr
Biotechnology, Healthcare and Hospitals
2026-04-01 8:00 AM EDT | Envoy Medical, Inc.
Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre.
Technology, Biotechnology, Investment Banking, Health
2026-04-01 7:30 AM EDT | Bloom Burton & Co. Inc.
Cardiol Therapeutics Announces Year-End 2025 Update on Operations
Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026. Reported positive Phase II ARCHER data showing CardiolRx™ significantly reduced left ventricular mass in patients with acute myocarditis; results published in ESC Heart Failure. Advanced CRD-38 program, a novel next generation drug intended for use in heart failure an
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-04-01 7:27 AM EDT | Cardiol Therapeutics Inc.
Scryb Reports 2026 AGM Results and Welcomes Veteran Capital Markets and Finance Directors
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") is pleased to announce the results of its Annual General Meeting of shareholders (the "AGM") held on March 31, 2026. All resolutions presented at the AGM received overwhelming shareholder support, with more than 99% of votes cast in favour. This strong approval reflects shareholder confidence in the Company's management team, leadership, refreshed strategy, and long-
Biotechnology, Healthcare and Hospitals, Health
2026-04-01 7:06 AM EDT | Scryb Inc.
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Calgary, Alberta--(Newsfile Corp. - March 31, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") is providing an update on the management cease trade order ("MCTO") application it made to the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The application remains under review, and no decision has yet been made by the ASC. The Company announced on March 17, 2026 (the "Original Announcement") that
Technology, Biotechnology, Healthcare and Hospitals
2026-03-31 7:09 PM EDT | Resverlogix Corp.
Dr. Christina Rahm Named One of MSN's "Top 10 Trailblazing Women in 2026"
Franklin, Tennessee--(Newsfile Corp. - March 31, 2026) - Dr. Christina Rahm, a recognized leader in science and innovation, has been selected as one of "MSN's Top 10 Trailblazing Women in 2026," a prestigious honor spotlighting women whose work is reshaping industries and driving meaningful impact across communities. The recognition appears in MSN's feature highlighting women at the forefront of change this year. "I'm truly honored to be featured in MSN's "Top 10 Trailbl
Biotechnology, Food / Beverages, Health
2026-03-31 6:03 PM EDT | DRC Ventures
BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc.
Biotechnology, Pharmaceuticals, Health
2026-03-31 4:02 PM EDT | BioHarvest Sciences Inc.
BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has successfully completed Stage 1 of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. The program is being conducted under a contract sig
Biotechnology, Pharmaceuticals, Health
2026-03-31 8:00 AM EDT | BioHarvest Sciences Inc.
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update
December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated Approval Pathway Pre-specified clinical outcomes data correlates with Immune biomarker signature Company positioned to review completed Phase 2b clinical & biomarker data and confirmatory Phase 3 trial protocol with U.S. FDA, EMA and U.K. MHRA in 2Q/26
2026-03-31 7:40 AM EDT | OS Therapies
Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, has appointed John Farlinger, currently chair of the Company's audit committee, as chief executive officer and chairman. In connection with Mr. Farlinger's appointment, the Company and Mr. Farlinger have entered i
2026-03-31 7:00 AM EDT | Telo Genomics Corp.
Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually
Toronto, Ontario--(Newsfile Corp. - March 31, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces it has secured a strategic commercial order for an initial
Technology, Biotechnology, Health
2026-03-31 6:30 AM EDT | Therma Bright Inc.
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply for future clinical trials. The company will manufacture Phio's lead compo
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-30 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy com
Technology, Biotechnology, Pharmaceuticals, Health
2026-03-30 7:00 AM EDT | TempraMed Technologies Ltd.
PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors. Dr. Pruthi is an accomplished physician-scientist and executi
Biotechnology, Pharmaceuticals, Health
2026-03-30 3:00 AM EDT | PreveCeutical Medical Inc.
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's
Biotechnology, Pharmaceuticals
2026-03-27 5:05 PM EDT | InMed Pharmaceuticals
Neural Therapeutics Announces Amendment to SIO Agreement, Concurrent Financing Terms, Shareholder Meeting Date and RSU Grant
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces that it has entered into a second amending agreement (the "SIO Amendment") to its strategic investment and option agreement dated May 26, 2025, as previously amended (the "SIO Agreement"), with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-03-27 7:30 AM EDT | Neural Therapeutics Inc.
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. -
2026-03-27 6:00 AM EDT | OS Therapies